These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18585971)

  • 21. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
    Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
    Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.
    Yuen MF; Fong DY; Wong DK; Yuen JC; Fung J; Lai CL
    Hepatology; 2007 Dec; 46(6):1695-703. PubMed ID: 18027877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum HBV DNA level at week 24 as a proper predictor for the effect of 2-year lamivudine treatment.
    Zheng Q; Jiang JJ; Chen J; Zhu YY; Liu YR; Chen YT
    Chin Med J (Engl); 2011 Apr; 124(8):1257-60. PubMed ID: 21543007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Song K; Rajvanshi P
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
    [No Abstract]   [Full Text] [Related]  

  • 32. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.
    Yalcin K; Degertekin H; Yildiz F; Celik Y
    Clin Infect Dis; 2003 Jun; 36(12):1516-22. PubMed ID: 12802750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.
    Sarin SK; Sood A; Kumar M; Arora A; Amrapurkar D; Sharma BC; Konar A; Chawla YK; Jain RK; Nanda V; Kumar A; Hissar S; Lavate P; Lahoti D;
    Am J Gastroenterol; 2007 Jan; 102(1):96-104. PubMed ID: 17266689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
    ter Borg MJ; van Zonneveld M; Zeuzem S; Senturk H; Akarca US; Simon C; Hansen BE; Haagmans BL; de Man RA; Schalm SW; Janssen HL;
    Hepatology; 2006 Sep; 44(3):721-7. PubMed ID: 16941701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
    Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.